Plasma plasminogen activator inhibitor-1 levels and nonalcoholic fatty liver in individuals with features of metabolic syndrome

Clinical and Applied Thrombosis/Hemostasis

Volumn 14, Issue 3, 2008, Pages 319-324

  De Larrañaga, Gabriela ^a   Wingeyer, Silvia Perés ^a   Graffigna, Mabel ^b   Belli, Susana ^b   Bendezú, Karla ^a   Álvarez, Silvia ^c   Levalle, Oscar ^b   Fainboim, Hugo ^a  

^a HOSPITAL F J MUÑIZ   (Argentina)

^b HOSPITAL DURAND   (Argentina)

^c HOSPITAL NACIONAL PROFESOR ALEJANDRO POSADAS   (Argentina)

Author keywords

Fatty liver; Insulin resistance; Liver fibrosis; Metabolic syndrome; PAI 1

Indexed keywords

AMINOTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD SAMPLING; BODY MASS; CONTROLLED STUDY; CORRELATION ANALYSIS; FAT CONTENT; FATTY LIVER; FEMALE; HISTOPATHOLOGY; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; RISK FACTOR; WAIST CIRCUMFERENCE;

ADIPOSITY; ADULT; BODY MASS INDEX; FATTY LIVER; FEMALE; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; PLASMINOGEN ACTIVATOR INHIBITOR 1; RISK FACTORS;

EID: 45749138414     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029607304094     Document Type: Article

References (33)

1. Eckel RH, Grundy SM, Zimmet PZ The metabolic syndrome. Lancet. 2005 ; 365: 415-428.
2. Dandona P., Aljada A., Chaudhuri A., et al. Metabolic syndrome. A comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation. 2005 ; 111: 1448-1454.
3. Alessi MC, Juhan-Vague I. PAI-1 and the metabolic syndrome: links, causes, and consequences. Arterioscler Thromb Vasc Biol. 2006 ; 26: 2200-2207.
4. Grundy SM Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab. 2004 ; 89: 2595-2600.
5. Pagano G., Pacini G., Musso G., et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology. 2002 ; 35: 367-372.
6. Angelico F., Del Ben M., Conti R., et al. Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease. J Clin Endocrinol Metab. 2005 ; 90: 1578-1582.
7. Marchesini G., Bugianesi E., Forlani G., et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003 ; 37: 917-923.
8. Marchesini G., Brizi M., Bianchi G., et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001 ; 50: 1844-1850.
9. Dixon JB, Bhathal PS, Hughes NR, et al. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology. 2004 ; 39: 1647-1654.
10. Fassio E., Alvarez E., Dominguez N., et al. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology. 2004 ; 40: 820-826.
11. Sorrentino P., Tarantino G., Conca P., et al. Silent nonalcoholic fatty liver disease-a clinical-histological study. J Hepatol. 2004 ; 41: 751-757.
12. Adams LA, Sanderson S., Lindor KD, et al. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol. 2005 ; 42: 132-138.
13. Lijnen HR Pleiotropic functions of plasminogen activator inhibitor-1. J Thromb Haemost. 2005 ; 3: 35-45.
14. Festa A., D'Agostino R., Tracy RP, et al. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes. 2002 ; 51: 1131-1137.
15. Mavri A., Alessi MC, Juhan-Vague I. Hypofibrinolysis in the insulin syndrome: implication in cardiovascular disease. J Intern Med. 2004 ; 255: 448-456.
16. Juhan-Vague I., Alessi MC, Mavri A., et al. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost. 2003 ; 1: 1575-1579.
17. Solano MP, Perry AC, Wang X., Ross R., Goldberg RB Insulin resistance but not visceral adipose tissue is associated with plasminogen activator inhibitor type 1 levels in overweight and obese premenopausal African-American women. Int J Obes Relat Metab Disord. 2003 ; 27: 82-87.
18. Meigs JB, Mittleman MA, Nathan DM, et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham offspring study. JAMA. 2000 ; 283: 221-228.
19. Cigolini M., Targher G., Agostino G., et al. Liver steatosis and its relation to plasma haemostatic factors in apparently healthy men. Role of the metabolic syndrome. Thromb Haemost. 1996 ; 76: 69-73.
20. Alessi MC, Bastelica D., Mavri A., et al. Plasma PAI-1 levels are more strongly related to liver steatosis than to adipose tissue accumulation. Arterioscler Thromb Vasc Biol. 2003 ; 23: 1262-1268.
21. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). Expert Panel of Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001 ; 285: 2486-2497.
22. Rosito GA, D'Agostino RB, Massaro J., et al. Association between obesity and prothrombotic state: the Framingham offspring study. Thromb Haemost. 2004 ; 91: 683-689.
23. Lijnen HR, Alessi MC, Van Hoef B., et al. On the role of plasminogen activator inhibitor-1 in adipose tissue development and insulin resistance in mice. J Thromb Haemost. 2005 ; 3: 1174-1179.
24. Ma LJ, Mao SL, Taylor KL, et al. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes. 2004 ; 53: 336-346.
25. Hoekstra T., Geleijnse JM, Schouten EG, et al. Plasminogen activator inhibitor-type-1: its plasma determinants and relation with cardiovascular risk. Thromb Haemost. 2004 ; 91: 861-872.
26. Bergheim I., Guo L., Davis MA, et al. Metformin prevents alcohol-induced liver injury in the mouse: critical role of plasminogen activator inhibitor-1. Gastroenterology. 2006 ; 130: 2099-2112.
27. Seppälä-Lindroos A., Vehkavaara S., Häkkinen AM, et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab. 2002 ; 87: 3023-3028.
28. Lonardo A., Lombardini S., Scaglioni F., et al. Hepatic steatosis and insulin resistance: does etiology make a difference ? J Hepatol. 2006 ; 44: 190-196.
29. Promrat K., Lutchman G., Uwaifo GI, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology. 2004 ; 39: 188-196.
30. Duseja A., Murlidharan R., Bhansali A., et al. Assessment of insulin resistance and effect of metformin in nonalcoholic steatohepatitis - a preliminary report. Indian J Gastroenterol. 2004 ; 23: 12-15.
31. Skurk T., Hauner H. Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1. Int J Obes Relat Metab Disord. 2004 ; 28: 1357-1364.
32. Palomba S., Orio F. Jr, Falbo A., et al. Plasminogen activator inhibitor 1 and miscarriage after metformin treatment and laparoscopic ovarian drilling in patients with polycystic ovary syndrome. Fertil Steril. 2005 ; 84: 761-765.
33. Bugianesi E., Manzini P., D'Antico S., et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology. 2004 ; 39: 179-187.